AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)

Harry P. Erba; Daniel A. Pollyea; Mikkael A. Sekeres; Guillermo Garcia-Manero; Karen Seiter; Irene S. DeGutis; Pavel Kiselev; Ali McBride; Edward Yu; Gail J. Roboz

doi:10.1016/S2152-2650(22)01254-X

Back

AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)

Journal article

Peer reviewed

AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)

Harry P. Erba, Daniel A. Pollyea, Mikkael A. Sekeres, Guillermo Garcia-Manero, Karen Seiter, Irene S. DeGutis, Pavel Kiselev, Ali McBride, Edward Yu and Gail J. Roboz

Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S229-S230

2022-10

DOI: https://doi.org/10.1016/S2152-2650(22)01254-X

Appears in Miller School of Medicine - Latest Publications

Metrics

2 Record Views

Details

Title: AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)
Creators: Harry P. Erba
Daniel A. Pollyea
Mikkael A. Sekeres
Guillermo Garcia-Manero
Karen Seiter
Irene S. DeGutis
Pavel Kiselev
Ali McBride
Edward Yu
Gail J. Roboz
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S229-S230
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031760216102976